4acp

From Proteopedia

proteopedia linkproteopedia link

Template:STRUCTURE 4acp

Contents 1 Deactivation of human IgG1 Fc by endoglycosidase treatment 2 Disease 3 About this Structure 4 Reference

Deactivation of human IgG1 Fc by endoglycosidase treatment

Template:ABSTRACT PUBMED 22484364

Disease

[IGHG1_HUMAN] Defects in IGHG1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving IGHG1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. Translocation t(11;14)(q13;q32) with CCND1; translocation t(4;14)(p16.3;q32.3) with FGFR3; translocation t(6;14)(p25;q32) with IRF4.

About this Structure

4acp is a 2 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

• Baruah K, Bowden TA, Krishna BA, Dwek RA, Crispin M, Scanlan CN. Selective Deactivation of Serum IgG: A General Strategy for the Enhancement of Monoclonal Antibody Receptor Interactions. J Mol Biol. 2012 Apr 5. PMID:22484364 doi:10.1016/j.jmb.2012.04.002